Clinical Trial Update: A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib safety lead-in followed by a Phase II trial evaluating ADG106 in combination with neoadjuvant chemotherapy for HER2-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ADG106

Snippet

Sponsor: National University Hospital, Singapore | Conditions: HER2-negative Breast Cancer, Advanced Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING